TCM

Which are the latest news on TCM?

Why is TCM Ltd falling/rising?

As of 05-Sep, TCM Ltd's stock price is rising to 44.50, reflecting a 1.74% increase due to strong relative performance and heightened investor participation. The stock's price exceeds its short-term moving averages, indicating positive investor sentiment despite being lower than longer-term averages.

As of 05-Sep, TCM Ltd's stock price is rising, currently at 44.50, with a change of 0.76 (1.74%) increase. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.82% today, indicating strong relative performance. Additionally, there has been a significant increase in investor participation, as evidenced by a delivery volume of 25.16k on September 3, which rose by 294.24% compared to the 5-day average delivery volume. <BR><BR>Moreover, the stock's current price is higher than its 5-day, 20-day, and 50-day moving averages, suggesting a positive short-term trend. Although it remains lower than the 100-day and 200-day moving averages, the overall performance today reflects a positive sentiment among investors. These factors combined contribute to the stock's rising price.

Who are in the management team of TCM?

The management team of TCM includes Joseph Varghese (Managing Director), Ramesh Babu (Executive Director), and Gokul V Shenoy (Company Secretary & Compliance Officer), along with several board members comprising both non-executive and independent directors.

The management team of TCM includes the following individuals:<BR><BR>1. **Joseph Varghese** - Managing Director<BR>2. **Ramesh Babu** - Executive Director<BR>3. **Gokul V Shenoy** - Company Secretary & Compliance Officer<BR><BR>Additionally, there are several board members who serve in non-executive and independent roles:<BR><BR>- **George Varghese** - Non-Executive & Non-Independent Director<BR>- **Rani Jose** - Non-Executive & Non-Independent Director<BR>- **Gopalakrishnan Mahesh** - Independent Director<BR>- **Jose Jacob** - Independent Director<BR>- **Sreenivasa Bhat** - Independent Director<BR>- **Bobby John** - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategy and operations.

What does TCM do?

TCM Ltd is a micro-cap company involved in trading and installing solar panels, manufacturing cattle feed, and operating in the commodity chemicals sector. As of June 2026, it reported net sales of 5 Cr and a net loss of 2 Cr, with a market cap of INR 31 Cr.

Overview:<BR>TCM Ltd is engaged in the trading and installation of solar panels, manufacturing of cattle feed, and operates within the commodity chemicals industry as a micro-cap company.<BR><BR>History:<BR>TCM Ltd was initially incorporated as 'Travancore Chemical & Mfg. Co. Ltd' in April 1943 and changed its name to TCM Limited on 10 September 1996. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 5 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: -2 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 31 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 26 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.87 <BR>Return on Equity: -23.52% <BR>Price to Book: 1.25<BR><BR>Contact Details:<BR>Address: 28/2917 Aiswarya Shanthi Nagar, Ponneth Temple Road Cochin Kerala : 682020 <BR>Tel: 91-0484-2316771 <BR>Email: info@tcmlimited.in <BR>Website: http://www.tcmlimited.in

Who are the peers of the TCM?

TCM's peers include Ritesh Intl., Gayatri BioOrga., Shreyas Interm., Camex, Haryana Leather, Advance Petroch., Deco-Mica, and Sonal Adhesives. Ritesh Intl. shows the highest 1-year return at 168.02%, while TCM has a return of 7.46%, and Gayatri BioOrga. has the lowest at -37.50%.

Peers: The peers of TCM are Ritesh Intl., Gayatri BioOrga., Shreyas Interm., Camex, Haryana Leather, Advance Petroch., Deco-Mica, and Sonal Adhesives.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ritesh Intl. and Haryana Leather, while Average management risk is found at TCM, Sonal Adhesives, and the rest. Below Average management risk is noted at Shreyas Interm., Camex, Deco-Mica, and Gayatri BioOrga. Growth is Good at Advance Petroch. and Sonal Adhesives, Average at Shreyas Interm., Camex, and TCM, while Below Average growth is seen at Ritesh Intl., Gayatri BioOrga., Haryana Leather, and Deco-Mica. Capital Structure is Good at Ritesh Intl. and Haryana Leather, Average at TCM and Advance Petroch., and Below Average at Shreyas Interm., Camex, Deco-Mica, and Sonal Adhesives.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Ritesh Intl. at 168.02%, while Gayatri BioOrga. has the lowest at -37.50%. TCM's 1-year return of 7.46% is higher than Gayatri BioOrga.'s but lower than Ritesh Intl.'s. Additionally, the six-month return is negative for Haryana Leather, Shreyas Interm., and Deco-Mica.

How big is TCM?

As of 31st August, TCM Ltd has a market capitalization of 31.00 Cr and reported net sales of 21.41 Cr with a loss of 5.17 Cr over the latest four quarters. Shareholder's funds are 30.52 Cr, and total assets are valued at 76.40 Cr.

As of 31st August, TCM Ltd has a market capitalization of 31.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, TCM Ltd reported net sales of 21.41 Cr. However, the company experienced a loss of 5.17 Cr during this period.<BR><BR>The latest annual reporting period for TCM Ltd is March 2025, with shareholder's funds amounting to 30.52 Cr and total assets valued at 76.40 Cr.

Should I buy, sell or hold TCM Ltd?

Are TCM Ltd latest results good or bad?

TCM Ltd's latest results are concerning, showing a net loss of ₹1.65 crore and a 35.69% drop in revenue year-over-year, indicating significant operational distress and ongoing challenges in maintaining profitability. Overall, the financial performance suggests a critical need for management to address these issues.

TCM Ltd's latest results are concerning and indicate significant operational distress. In the fourth quarter of FY26, the company reported a net loss of ₹1.65 crore, which is a staggering 140.94% decline year-over-year. Revenue also fell sharply by 35.69% compared to the same quarter last year, coming in at ₹4.92 crore. This marks a continued trend of declining sales, as the company has faced negative operating margins for six consecutive quarters, with the latest operating margin at -23.78%.<BR><BR>The financial performance highlights a company struggling to maintain profitability, with cash flow challenges compounding the issues. The return on equity is a mere 0.55%, and the overall financial health appears weak, with a deteriorating balance sheet and no positive cash flow from operations.<BR><BR>While the stock did see a short-term bounce, closing up 4.93% recently, the underlying fundamentals suggest that the company's operational challenges are structural rather than temporary. Given these factors, the latest results can be classified as bad, reflecting a critical need for management to address these ongoing issues to restore viability and investor confidence.

When is the next results date for TCM Ltd?

The next results date for TCM Ltd is 26 May 2026.

The next results date for TCM Ltd is scheduled for 26 May 2026.

How has been the historical performance of TCM?

TCM's historical performance shows significant fluctuations, with net sales peaking at 32.23 Cr in March 2024 before declining to 26.01 Cr in March 2025. However, the company reported a recovery in profitability, achieving a profit after tax of 1.40 Cr in March 2025, up from a loss of 2.29 Cr the previous year.

Answer:<BR>The historical performance of TCM shows significant fluctuations in its financial metrics over the years, with a notable recovery in recent periods.<BR><BR>Breakdown:<BR>TCM's net sales peaked at 32.23 Cr in March 2024 but fell to 26.01 Cr in March 2025, following a substantial increase from just 7.35 Cr in March 2023. The total operating income mirrored this trend, reaching 32.23 Cr in March 2024 before declining to 26.01 Cr in March 2025. The company's total expenditure, excluding depreciation, was 28.17 Cr in March 2025, down from 34.47 Cr in March 2024, indicating a reduction in costs. Despite this, TCM reported an operating profit (PBDIT) of 2.31 Cr in March 2025, a recovery from a loss of 1.81 Cr in March 2024. The profit before tax also improved to 1.37 Cr in March 2025, compared to a loss of 2.25 Cr in the previous year. Consequently, the profit after tax turned positive at 1.40 Cr in March 2025, reversing a loss of 2.29 Cr in March 2024. The consolidated net profit for March 2025 was 1.61 Cr, a significant improvement from the loss of 1.95 Cr in March 2024. TCM's total assets decreased to 76.40 Cr in March 2025 from 83.79 Cr in March 2024, while total liabilities also fell to 76.40 Cr from 83.79 Cr, indicating a stabilization in the company's financial position. The cash flow from operating activities was negative at -10.00 Cr in March 2025, although cash flow from financing activities showed a positive inflow of 10.00 Cr. Overall, TCM's financial performance reflects a recovery trajectory, with improvements in profitability metrics despite challenges in sales and cash flow.

Who are the top shareholders of the TCM?

The top shareholder of TCM is Joseph Varghese, holding 49.48%, with no pledged promoter holdings. The highest public shareholder is Lici Asm Non Par at 7.41%, while individual investors collectively own 38.8% of the shares.

The top shareholders of TCM include the promoters, with Joseph Varghese holding the largest share at 49.48%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors currently do not hold any shares in the company. The highest public shareholder is Lici Asm Non Par, who owns 7.41%. Additionally, individual investors collectively hold 38.8% of the shares.

Is TCM overvalued or undervalued?

As of April 25, 2023, TCM is considered risky and overvalued with a PE Ratio of 18.69 and an EV to EBITDA of -19.11, significantly underperforming compared to peers like UPL and BASF India, and has a year-to-date return of -14.82% versus the Sensex's 5.59%.

As of 25 April 2023, TCM's valuation grade has moved from does not qualify to risky, indicating a shift in its perceived investment quality. The company is currently assessed as overvalued given its financial ratios and performance metrics. Key ratios include a PE Ratio of 18.69, an EV to EBITDA of -19.11, and a ROE of 5.31%. <BR><BR>In comparison to peers, TCM's valuation stands out unfavorably; for instance, UPL, which is rated as attractive, has a PE Ratio of 38.74 and an EV to EBITDA of 8.35. Similarly, BASF India, also attractive, shows a PE Ratio of 45.64 and an EV to EBITDA of 28.4. Furthermore, TCM's recent stock performance has lagged behind the Sensex, particularly in the year-to-date return of -14.82% compared to the Sensex's 5.59%, reinforcing the notion that TCM is overvalued in the current market context.

What is the technical trend for TCM?

As of June 5, 2025, TCM's technical trend has shifted to a bearish stance with moderate strength, driven by bearish signals from moving averages and Bollinger Bands, despite some mixed momentum indicators.

As of 5 June 2025, the technical trend for TCM has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this assessment include the bearish signals from the daily moving averages and the Bollinger Bands on both weekly and monthly time frames. The MACD shows a mildly bullish signal on the weekly but is bearish on the monthly, indicating mixed momentum. The KST is mildly bullish weekly but bearish monthly, further contributing to the overall bearish outlook. The Dow Theory indicates a mildly bullish stance on the weekly but no trend on the monthly, suggesting uncertainty in the longer term. Overall, the bearish trend is supported by the prevailing indicators despite some mixed signals.

Has TCM declared dividend?

No Dividend History Available